Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Andrews

Showing results (581-590 of 661) with videos related to

Pageof 67
Sort By:
RSC Medicinal Chemistry|October 20, 2023
The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)Gregory G Aldred, Timothy P C Rooney, Henriette M G Willems, et al.
RSC Medicinal Chemistry|May 30, 2023
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitorHenriëtte M G Willems, Simon Edwards, Helen K Boffey, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|April 11, 2017
Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studiesPaul Ratner, Charles P Andrews, Frank C Hampel, et al.
International Journal of Pharmaceutics|June 26, 2021
Continuous manufacture of hydroxychloroquine sulfate drug products via hot melt extrusion technology to meet increased demand during a global pandemic: From bench to pilot scaleVictoire de Margerie, Christopher McConville, Suha M Dadou, et al.
International Journal of Pharmaceutics|May 7, 2018
A comparative study between hot-melt extrusion and spray-drying for the manufacture of anti-hypertension compatible monolithic fixed-dose combination productsJ F Kelleher, G C Gilvary, A M Madi, et al.
Cancer Research|September 25, 2010
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2Ekaterina V Kalashnikova, Alexey S Revenko, Abigael T Gemo, et al.
Plos One|February 27, 2015
Aberrant lymphatic endothelial progenitors in lymphatic malformation developmentJune K Wu, Christopher Kitajewski, Maia Reiley, et al.
Infection and Immunity|February 20, 1999
Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestisG P Andrews, S T Strachan, G E Benner, et al.
Children (Basel, Switzerland)|April 23, 2022
The Current States, Challenges, Ongoing Efforts, and Future Perspectives of Pharmaceutical Excipients in Pediatric Patients in Each Country and RegionJumpei Saito, Anjali Agrawal, Vandana Patravale, et al.
Journal of Natural Products|September 1, 1991
The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practicesD E Schaufelberger, M P Koleck, J A Beutler, et al.
Pageof 67

Showing results (581-590 of 661) with videos related to

Sort By:
Pageof 67
RSC Medicinal Chemistry|October 20, 2023
The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)Gregory G Aldred, Timothy P C Rooney, Henriette M G Willems, et al.
RSC Medicinal Chemistry|May 30, 2023
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitorHenriëtte M G Willems, Simon Edwards, Helen K Boffey, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|April 11, 2017
Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studiesPaul Ratner, Charles P Andrews, Frank C Hampel, et al.
International Journal of Pharmaceutics|June 26, 2021
Continuous manufacture of hydroxychloroquine sulfate drug products via hot melt extrusion technology to meet increased demand during a global pandemic: From bench to pilot scaleVictoire de Margerie, Christopher McConville, Suha M Dadou, et al.
International Journal of Pharmaceutics|May 7, 2018
A comparative study between hot-melt extrusion and spray-drying for the manufacture of anti-hypertension compatible monolithic fixed-dose combination productsJ F Kelleher, G C Gilvary, A M Madi, et al.
Cancer Research|September 25, 2010
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2Ekaterina V Kalashnikova, Alexey S Revenko, Abigael T Gemo, et al.
Plos One|February 27, 2015
Aberrant lymphatic endothelial progenitors in lymphatic malformation developmentJune K Wu, Christopher Kitajewski, Maia Reiley, et al.
Infection and Immunity|February 20, 1999
Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestisG P Andrews, S T Strachan, G E Benner, et al.
Children (Basel, Switzerland)|April 23, 2022
The Current States, Challenges, Ongoing Efforts, and Future Perspectives of Pharmaceutical Excipients in Pediatric Patients in Each Country and RegionJumpei Saito, Anjali Agrawal, Vandana Patravale, et al.
Journal of Natural Products|September 1, 1991
The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practicesD E Schaufelberger, M P Koleck, J A Beutler, et al.
Pageof 67